Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Precancerous Conditions 32Neoplasms, Plasma Cell 10Multiple Myeloma 10Lymphoma 10Leukemia 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Monoclonal Gammopathy of Undetermined Significance 8Lymphoma, T-Cell, Cutaneous 8Lymphoma, Non-Hodgkin 8Lymphoma, Mantle-Cell 8Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Large-Cell, Anaplastic 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 8Leukemia, Lymphocytic, Chronic, B-Cell 8Immunoglobulin Light-chain Amyloidosis 8Immunoblastic Lymphadenopathy 8Hodgkin Disease 8Waldenstrom Macroglobulinemia 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Myeloproliferative Disorders 7Lymphoma, B-Cell, Marginal Zone 7Leukemia, Prolymphocytic 7Leukemia, Large Granular Lymphocytic 7Leukemia, Hairy Cell 7Keratosis, Actinic 7Burkitt Lymphoma 7Thrombocythemia, Essential 6Sezary Syndrome 6Primary Myelofibrosis 6

Interventions

venetoclax 1fludarabine 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Venentoclax × Other neoplasm × Clear all
NCT07396480 2026-03-17

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

First Affiliated Hospital of Zhejiang University

Phase 3 Recruiting
186 enrolled
Other neoplasm

Venentoclax

Data powered by HemOnc (CC BY 4.0) Colophon âš¡